Simponi50 mg/0.5 ml

Simponi is a human monoclonal antibody (TNF-alpha inhibitor) approved for the following conditions:

• Moderate-to-severe active rheumatoid arthritis (RA) in adults, used in combination with methotrexate (FDA-approved, established use).
• Active psoriatic arthritis (PsA) in adults, alone or in combination with methotrexate (FDA-approved, established use).
• Active ankylosing spondylitis (AS) in adults (FDA-approved, established use).
• Moderate-to-severe active ulcerative colitis (UC) in adults who have had an inadequate response to, or are intolerant of, conventional therapy (FDA-approved, established use).

The intravenous formulation of Simponi is additionally approved, in some markets, for polyarticular juvenile idiopathic arthritis and pediatric psoriatic arthritis in patients 2 years of age and older (guideline/label-supported pediatric extension; see Use in Special Populations). Simponi is not indicated for infectious or non-autoimmune forms of arthritis.

Simponi is a fully human IgG1 kappa monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha), a key pro-inflammatory cytokine involved in the pathogenesis of chronic autoimmune inflammatory diseases.

Simponi is produced using recombinant DNA technology in a murine hybridoma cell line and is administered as a subcutaneous injection (self-administered or by a caregiver after training) or, in an alternate formulation, as an intravenous infusion given by a healthcare professional.

Golimumab binds with high affinity to both the soluble and transmembrane bioactive forms of human TNF-alpha, preventing TNF-alpha from binding to its cell-surface receptors (p55 and p75).

By neutralizing TNF-alpha activity, Golimumab reduces downstream inflammatory signalling, including expression of adhesion molecules responsible for leukocyte migration and infiltration, and lowers levels of other inflammatory mediators such as interleukin-6 (IL-6), C-reactive protein (CRP), and matrix metalloproteinases. This translates clinically into reduced joint inflammation, reduced intestinal mucosal inflammation, and slowed structural (radiographic) damage in inflammatory arthritis.

Peak serum concentrations of Golimumab after subcutaneous injection are typically reached in about 2-6 days, with an elimination half-life of approximately 12 days.

Simponi subcutaneous injection is administered into the thigh, abdomen (avoiding the 2-inch area around the navel), or outer upper arm, rotating injection sites and avoiding areas that are tender, bruised, red, or hard.

The pre-filled syringe/pen should be allowed to reach room temperature (about 30 minutes) before injection and should not be shaken. Only a healthcare professional or a patient/caregiver specifically trained in subcutaneous self-injection technique should administer Simponi.

The intravenous formulation of Simponi must be diluted and administered only by a qualified healthcare professional experienced in biologic infusion therapy, as an infusion over approximately 30 minutes, with the patient monitored during and for a period after the infusion for infusion-related reactions.

Live vaccines: Live or live-attenuated vaccines should not be given concurrently with Simponi because of the risk of infection from the vaccine strain due to immunosuppression.

Other biologic DMARDs (e.g., anakinra, abatacept, other TNF inhibitors): Concurrent use with Simponi is not recommended because of an increased risk of serious infection without added clinical benefit.

Methotrexate: Combination with methotrexate is an established, often preferred, therapeutic strategy for rheumatoid arthritis and does not represent a harmful interaction; methotrexate may modestly increase Simponi serum concentrations.

CYP450 substrates: Chronic inflammation suppresses certain cytochrome P450 enzymes; by reducing inflammation, Simponi may normalize CYP450 activity, potentially altering levels of narrow-therapeutic-index drugs metabolized by these enzymes (e.g., warfarin, cyclosporine, theophylline) — monitoring is advised when starting or stopping Simponi in patients on such drugs.

Common (may affect more than 1 in 10-100 people):

• Upper respiratory tract infection, nasopharyngitis
• Injection-site reactions (erythema, itching, pain, swelling)
• Mild elevations in liver enzymes
• Hypertension

Serious (less common but clinically important):

• Serious infections (bacterial, tuberculosis reactivation, invasive fungal, viral, other opportunistic infections)
• Malignancies, including lymphoma (class warning for TNF inhibitors)
• New-onset or worsening congestive heart failure
• Demyelinating disorders (e.g., new-onset or exacerbated multiple sclerosis-like symptoms)
• Serious hypersensitivity reactions, including anaphylaxis
• Hepatotoxicity and cytopenias (rare)

See Precautions and Warnings for details on monitoring for these serious effects during treatment with Simponi.

Pregnancy: Data on use of Simponi in pregnancy are limited. Monoclonal antibodies such as Simponi are actively transported across the placenta, particularly in the third trimester, and may affect immune response in the exposed infant. Simponi should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; use should be under close physician supervision. Administration of live vaccines to infants exposed to Simponi in utero should generally be delayed for several months after birth — consult a pediatrician.

Lactation: It is not known with certainty whether clinically significant amounts of Simponi pass into human breast milk; as an antibody, transfer is expected to be minimal, but a decision on breastfeeding during treatment with Simponi should be made in consultation with a physician, weighing the benefits of breastfeeding against the mother's clinical need for the drug.

Serious infections: Simponi increases susceptibility to serious infections, including reactivation of latent tuberculosis and hepatitis B. All patients must be screened for latent tuberculosis and hepatitis B infection before starting Simponi, and monitored for signs of infection throughout treatment; discontinue promptly if a serious infection develops.

Malignancy: TNF inhibitors, including Simponi, have been associated with an increased risk of lymphoma and other malignancies, particularly in children and adolescents treated with TNF blockers.

Heart failure: New onset or worsening of congestive heart failure has been reported; use with caution in patients with pre-existing heart failure, and discontinue if new or worsening symptoms occur.

Demyelinating disease: Rare cases of new-onset or exacerbated central nervous system demyelinating disorders have been reported; use with caution in patients with a history of such conditions.

Administration requirement: Simponi should only be prescribed and monitored by, or administration supervised by, a healthcare professional experienced in the diagnosis and treatment of the conditions for which it is indicated and familiar with biologic therapy risks.

Hypersensitivity: See Contraindications for hypersensitivity reactions; discontinue immediately and treat appropriately if anaphylaxis or a serious allergic reaction occurs during or after administration of Simponi.

Autoimmune reactions: Rare cases of lupus-like syndrome have been reported; discontinue Simponi if such a syndrome develops.

There is no established antidote for Simponi overdose. In clinical studies, intravenous doses up to 10 mg/kg were administered without dose-limiting toxicity.

In case of a suspected overdose of Simponi, the patient should be closely monitored for any signs or symptoms of adverse reactions (particularly signs of infection or hypersensitivity), and supportive/symptomatic treatment instituted promptly. Seek immediate medical attention or contact emergency services / a poison control center if an overdose is suspected.

Elderly: No overall dose adjustment is required in elderly patients; however, since the incidence of serious infections and malignancies is generally higher in older individuals, Simponi should be used with caution and close monitoring in this group.

Renal and hepatic impairment: Formal studies of Simponi in patients with renal or hepatic impairment have not been conducted; specific dose adjustment recommendations are not established. Use with caution and monitor liver function periodically.

Pediatric use: See Pediatric Uses.

Treatment duration with Simponi is individualized based on indication and clinical response. For rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, clinical response is typically assessed by around 12-14 weeks (3-4 monthly doses); if no meaningful improvement is seen by this point, continued therapy with Simponi should be reconsidered.

For ulcerative colitis, response to induction dosing is generally assessed by Week 6; patients who do not respond adequately by this time should not continue maintenance therapy with Simponi. In patients who do respond, treatment may continue long-term with ongoing monitoring for safety.

Biologic Response Modifier; Tumor Necrosis Factor-alpha (TNF-alpha) Inhibitor; Disease-Modifying Antirheumatic Drug (DMARD)

Golimumab is a human IgG1 kappa monoclonal antibody that binds with high affinity to both the soluble and transmembrane bioactive forms of human tumor necrosis factor-alpha (TNF-alpha), forming stable complexes that neutralize TNF-alpha bioactivity.

By preventing TNF-alpha from engaging its cell-surface receptors, Golimumab inhibits downstream pro-inflammatory processes — including cytokine production, expression of endothelial adhesion molecules, and leukocyte recruitment — that drive the chronic inflammation seen in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.

B

The safety and efficacy of the subcutaneous formulation of Simponi have not been established in patients under 18 years of age for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or ulcerative colitis.

The intravenous formulation of Simponi has been studied and, in some regulatory markets, approved for polyarticular juvenile idiopathic arthritis and psoriatic arthritis in pediatric patients 2 years of age and older, using weight/body-surface-area-based dosing. Pediatric use of Simponi, where undertaken, should only be initiated and supervised by a pediatric rheumatology or gastroenterology specialist familiar with biologic therapy.